Insulet (NASDAQ:PODD) Director Michael Minogue Acquires 2,030 Shares

Insulet Corporation (NASDAQ:PODD) Director Michael Minogue acquired 2,030 shares of Insulet stock in a transaction on Wednesday, February 25th. The shares were purchased at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Insulet Price Performance

Shares of PODD stock opened at $251.50 on Friday. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88. The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. The stock has a fifty day simple moving average of $269.07 and a two-hundred day simple moving average of $303.58. The stock has a market capitalization of $17.71 billion, a price-to-earnings ratio of 71.86, a P/E/G ratio of 1.48 and a beta of 1.41.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company had revenue of $783.80 million during the quarter, compared to analyst estimates of $768.31 million. During the same period in the prior year, the firm earned $1.15 earnings per share. The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

PODD has been the topic of several research reports. Evercore set a $340.00 price objective on shares of Insulet in a report on Thursday, February 19th. Canaccord Genuity Group cut their price target on Insulet from $450.00 to $435.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Oppenheimer cut their price target on Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. BTIG Research restated a “buy” rating and set a $380.00 price objective on shares of Insulet in a research note on Wednesday, February 18th. Finally, Citigroup dropped their price objective on Insulet from $380.00 to $345.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Twenty analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $354.57.

Institutional Investors Weigh In On Insulet

A number of large investors have recently modified their holdings of PODD. Larson Financial Group LLC boosted its stake in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Insulet in the fourth quarter worth $26,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet during the fourth quarter worth $28,000. DV Equities LLC purchased a new stake in shares of Insulet during the fourth quarter valued at $28,000. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet in the 4th quarter valued at $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.